Low T - Health Risks of Testosterone Therapy - Mayo Clinic

Mayo Clinic on TRT Risks: Medical Authority Meets Real-World Concerns

When the Mayo Clinic puts out a video on testosterone therapy, people pay attention, and for good reason. This is one of the most respected medical institutions in the world, and their perspective carries weight that a typical YouTube health channel simply cannot match. This video addresses the health risks of testosterone therapy head-on, and it is the kind of content that every man considering TRT should watch before making a decision.

That said, watching it with the right context matters. The Mayo Clinic, like most large academic medical centers, tends to be conservative in its approach to hormone therapy. This is not a criticism. Conservatism in medicine often means protecting patients from unnecessary risk. But it does mean that the framing here may lean more heavily toward caution than what you would hear from a TRT-focused clinician. Both perspectives have value, and the most informed patients are the ones who consider both.

Cardiovascular Risk: The Biggest Question in TRT

The relationship between testosterone therapy and cardiovascular health has been one of the most debated topics in men's health over the last decade. Early observational studies raised alarms about increased heart attack and stroke risk in men on TRT, leading to an FDA warning that persists to this day. The Mayo Clinic video addresses this concern, and it is worth unpacking the full picture.

The landmark TRAVERSE trial, published in 2023, was specifically designed to answer the cardiovascular safety question. This was a large, randomized, placebo-controlled trial involving over 5,000 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. The result: testosterone therapy did not increase the rate of major adverse cardiovascular events compared to placebo. This was a significant finding because it challenged the narrative that TRT is inherently dangerous for the heart.

However, the TRAVERSE trial also showed that testosterone therapy was associated with higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury, though these events were relatively uncommon. The takeaway is not that TRT is risk-free for the heart, but rather that the cardiovascular risk appears to be lower than previously feared, especially when TRT is managed properly with appropriate monitoring.

Polycythemia: The Risk Nobody Talks About Enough

If there is one side effect of TRT that deserves more attention, it is polycythemia, the elevation of red blood cell count and hematocrit. Testosterone stimulates erythropoiesis (red blood cell production), and in some men, this effect can push hematocrit to dangerously high levels. Elevated hematocrit increases blood viscosity, which raises the risk of blood clots, stroke, and other cardiovascular events.

The Mayo Clinic rightly flags this as a significant concern, and it is one area where their conservative stance is entirely justified. Regular monitoring of CBC (complete blood count) is essential for every man on TRT. If hematocrit rises above 52 to 54 percent, intervention is needed. Options include reducing the testosterone dose, switching to a different delivery method (topical preparations tend to cause less polycythemia than injections), increasing injection frequency to reduce peaks, or therapeutic phlebotomy.

What the video might not emphasize enough is that polycythemia is a manageable side effect. It is not a reason to avoid TRT altogether. It is a reason to work with a provider who monitors your bloodwork consistently and knows how to adjust your protocol when needed.

Prostate Health and the PSA Question

The concern about testosterone and prostate cancer has been one of the biggest barriers to TRT adoption, and the science has shifted significantly on this topic over the past two decades. The old fear was based on the observation that prostate cancer is an androgen-sensitive disease and that castration (removing testosterone) could slow advanced prostate cancer growth. The logical extension was that adding testosterone must accelerate prostate cancer. This logic turned out to be too simplistic.

Current evidence suggests that testosterone replacement to physiological levels does not increase the risk of developing prostate cancer. The saturation model, proposed by Dr. Abraham Morgentaler, argues that androgen receptors in prostate tissue become fully saturated at relatively low testosterone levels, and additional testosterone beyond that point does not provide further growth stimulation. Multiple large studies and meta-analyses have supported this model.

That said, men with active prostate cancer should not take testosterone. And PSA monitoring remains an important part of TRT management, not because TRT causes cancer, but because PSA changes can indicate issues that warrant investigation regardless of their cause.

Fertility, Sleep Apnea, and Other Concerns

The video touches on several other risk areas that deserve attention. Fertility suppression is a real and significant concern. Exogenous testosterone shuts down the HPG axis, reducing or eliminating sperm production in most men. For men who want to preserve fertility, this needs to be addressed upfront, either by avoiding TRT in favor of alternatives like clomiphene or by using HCG concurrently to maintain testicular function.

Sleep apnea is another concern that comes up frequently. The evidence here is mixed. Some studies suggest testosterone can worsen obstructive sleep apnea, while others show no effect or even improvement. The practical approach is to screen for sleep apnea before starting TRT and monitor for worsening symptoms during treatment. If sleep apnea is present, it should be treated independently, as untreated sleep apnea can actually suppress testosterone production.

Who Should Watch This

This video is most valuable for men who want a mainstream medical perspective on TRT risks before making a treatment decision. It is the kind of content you might want to watch before your appointment with a urologist or endocrinologist, as it will help you ask better questions. It is also useful for family members or partners who are concerned about the safety of TRT and want reassurance from a trusted medical source.

If you are already on TRT and well-monitored, the information here will mostly reinforce things you already know. But it is a solid refresher on why consistent bloodwork and a knowledgeable provider are essential parts of responsible TRT management.

Building a Monitoring Routine That Protects You

The difference between safe TRT and risky TRT is monitoring. A thorough monitoring schedule turns the theoretical risks discussed in this video into manageable, actionable data points rather than vague fears. At minimum, every man on TRT should have the following checked on a regular basis: CBC with hematocrit (to catch polycythemia), thorough metabolic panel (to monitor kidney and liver function), lipid panel (to track cardiovascular risk markers), estradiol via sensitive assay (to manage aromatization), total and free testosterone (to verify dosing adequacy), and PSA for men over 40 (to monitor prostate health).

The timing of these labs matters. Baseline labs should be drawn before starting TRT, with follow-up at 6 to 8 weeks after starting or after any dose change, then at 3 months, 6 months, and annually on a stable protocol. Additional labs should be drawn anytime you experience new or worsening symptoms that could be treatment-related. This cadence catches problems early when they are easiest to manage and provides the longitudinal data your provider needs to optimize your protocol over time.

Beyond bloodwork, regular blood pressure monitoring is important since TRT can increase blood pressure in some men through fluid retention and increased red blood cell mass. A home blood pressure monitor is an inexpensive tool that provides data between office visits. Target blood pressure should be below 130/80 mmHg for most men, and persistent elevation warrants evaluation and potential treatment regardless of TRT status.

Putting Risk in Perspective

The framing of risk is important. Every medication carries risks, and TRT is no exception. But the risks need to be weighed against the consequences of untreated hypogonadism, which include increased visceral fat, insulin resistance, metabolic syndrome, cardiovascular disease, osteoporosis, depression, cognitive decline, and reduced quality of life. These are not trivial outcomes. They are the same conditions that the medical system spends billions of dollars treating every year.

For a man with confirmed symptomatic hypogonadism, the question is not whether TRT carries risk. It is whether the risks of treatment are greater or lesser than the risks of leaving the condition untreated. For most men who are appropriately selected, properly monitored, and managed by a knowledgeable provider, the evidence increasingly supports that the benefits outweigh the risks. The Mayo Clinic's cautious approach is valuable as a reminder to take the risks seriously and monitor diligently, but it should not be interpreted as a blanket warning against TRT for men who genuinely need it.

The Mayo Clinic video is an important reminder that informed consent and diligent monitoring are the foundation of safe TRT. Use the information here to build your knowledge base, develop a monitoring routine with your provider, and approach your treatment as a long-term partnership between you and your healthcare team. The goal is not to eliminate risk entirely. That is impossible with any medical intervention. The goal is to manage risk intelligently so that the benefits of treatment can be realized safely over the long term.